Anavex Life Sciences Announces Expansion of Leadership Team
Retrieved on:
Mercoledì, Maggio 22, 2024
Marketing, Drug, Gen-Probe, European Medicines Agency, FDA, Drug development, North Carolina State University, Senior, Rett syndrome, HCV, Therapy, Pharmacology, Clinical research, Ritonavir, MD, James Madison University, Ipilimumab, AbbVie, CNS, Clinical pharmacology, Bristol Myers Squibb, New Drug Application, Arena Pharmaceuticals, Nobel Prize, Schizophrenia, Nivolumab, Amylin Pharmaceuticals, Yale University, Molecular biology, Pharmacokinetics, Doctor of Philosophy, Acer, Rochester Institute of Technology, Research and development, University, Overalls, Pramlintide, Intercept Pharmaceuticals, DSM-IV codes, Assistant, EMA, DMPK, Roche, Development, Central nervous system, Pharmaceutical industry
“The most important part of building a long-term, commercially sustainable, growing business is putting the right players on the field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
Key Points:
- “The most important part of building a long-term, commercially sustainable, growing business is putting the right players on the field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
- Prior to Anavex Dr. Lopez-Talavera held key leadership positions at Fractyl Health, Intercept Pharmaceuticals, AbbVie, Bristol Myers Squibb and Roche.
- Dr. Edwards brings to Anavex 18 years of experience in various aspects of drug development including DMPK (drug metabolism and pharmacokinetics), Clinical Pharmacology, and Clinical Science.
- Before joining Anavex, Dr. Edwards served as Vice President of Clinical Science at Acer Therapeutics, and positions of increasing responsibility at Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals, and Arena Pharmaceuticals.